Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Relay Therapeutics, Inc. (RLAY : NSDQ)

• Company Description    Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 261

• Price / Volume Information    Yesterday's Closing Price: $6.05 Daily Weekly Monthly 20 Day Moving Average: 2,171,145 shares Shares Outstanding: 173.32 (millions) Market Capitalization: $1,048.60 (millions) Beta: 1.75 52 Week High: $7.64 52 Week Low: $1.78 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.92% -9.36% 12 Week 70.90% 63.82% Year To Date 46.85% 28.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 HAMPSHIRE STREET - CAMBRIDGE,MA 02139 USA ph: 617-370-8837 fax: - investors@relaytx.com http://www.relaytx.com

• General Corporate Information    Officers Sanjiv K. Patel - Chief Executive Officer; President and Director Thomas Catinazzo - Chief Financial Officer Alexis Borisy - Director Linda A. Hill - Director Douglas S. Ingram - Director Peer Information Relay Therapeutics, Inc. (GSAC) Relay Therapeutics, Inc. (CASI) Relay Therapeutics, Inc. (ALCD.) Relay Therapeutics, Inc. (OMNN) Relay Therapeutics, Inc. (CGPI.) Relay Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 75943R102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/25/26 Share - Related Items Shares Outstanding: 173.32 Most Recent Split Date: (:1) Beta: 1.75 Market Capitalization: $1,048.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 13.26% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/25/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 31.75% vs. Previous Quarter: -4.88% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -91.18% ROE 09/30/25 - -42.94 06/30/25 - -41.49 03/31/25 - -44.17 ROA 09/30/25 - -38.78 06/30/25 - -37.43 03/31/25 - -39.53 Current Ratio 09/30/25 - 19.14 06/30/25 - 20.92 03/31/25 - 19.96 Quick Ratio 09/30/25 - 19.14 06/30/25 - 20.92 03/31/25 - 19.96 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -3,561.43 06/30/25 - -3,728.45 03/31/25 - -4,341.53 Book Value 09/30/25 - 3.52 06/30/25 - 3.88 03/31/25 - 4.23 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©